Reducing total fatty acid content in crude glycerine using oleosorb
OleoSorb™ offers a novel solution to reduce Total Fatty Acid (TFA) content in crude glycerine to below 0.2% without affecting yield or quality. This multi-component adsorption technology is compatible with existing glycerine production processes.
Overview
OleoSorb™ is an innovative multi-component adsorption technology designed to significantly reduce the Total Fatty Acid (TFA) content in crude glycerine. By lowering TFA levels from typical values of 0.5-0.6% to under 0.2%, OleoSorb™ enhances the quality of crude glycerine while ensuring that the glycerine yield remains unaffected. This technology seamlessly integrates with existing glycerine production processes, offering an efficient and scalable solution for producers seeking to improve product quality.
Technical specifications
OleoSorb™ is comprised of three key components:
- Calcium Silicate Nanoparticles: These particles have high adsorptive properties, effectively capturing TFA molecules.
- Carboxymethyl Cellulose: This component forms a gel-like barrier, aiding in the separation of TFA from glycerine.
- Rosemary Extract Polyphenols: These polyphenols bind residual fatty acids, preventing oxidation and further reducing TFA content. All components are Generally Recognized as Safe (GRAS) and comply with European Food Safety Authority (EFSA) standards. OleoSorb™ is tested at various stages of the glycerine recovery process, ensuring compatibility and efficiency.
Technology readiness level
Currently at Technology Readiness Level 4, OleoSorb™ has been validated in lab-scale settings. A comprehensive study involving pilot-scale applications is underway to confirm efficacy, cost-effectiveness, and scalability. This study will inform the pathway to full-scale commercial implementation.
About Veos Pharmaceuticals
Veos Pharmaceuticals is a Madrid-based biotechnology company that develops and commercializes science-backed solutions across human health, agriculture, and environmental sustainability. Founded in 2023, the company operates as a vertically integrated entity, maintaining direct control over research, formulation, regulatory compliance, and distribution across Europe and North America. Its platform-based innovation model is built on scientific rigor and commercial discipline, resulting in a portfolio of more than 40 commercial products. By combining internal R&D with selective in-licensing and strategic partnerships, Veos translates validated research into scalable, real-world applications. The firm distinguishes itself through its focus on profitability, which it has maintained since 2024, and its commitment to manufacturing standards, leveraging European facilities to ensure quality and regulatory adherence.
The company's work provides critical value to diverse stakeholders, including patients, clinicians, growers, and industrial partners. Its human health platform delivers pharmaceutical and nutraceutical products targeting areas such as ophthalmology and muscle health, while its agricultural and environmental platforms focus on enhancing crop resilience, water treatment, and material recovery. Through its direct-to-consumer and business-to-business channels, Veos addresses specific market needs with evidence-based technologies. The company’s growth is supported by a senior leadership team with extensive expertise in pharmaceutical operations and biotechnology, and it actively collaborates with research institutions and global distributors to expand the deployment and impact of its technologies.
Inquire about this partnering listing
Industry applications
delivered to your inbox.